Ποια είναι η τιμή για Theradiag S.A. (ALTER)

Η τιμή για Theradiag S.A. (ALTER) είναι $1.38

Ποια είναι η κεφαλαιοποίηση αγοράς για Theradiag S.A. (ALTER)

Η κεφαλαιοποίηση αγοράς για Theradiag S.A. (ALTER) είναι $12.52M

Theradiag S.A. (ALTER) Κέρδη

Theradiag S.A. specializes in the creation, production, and marketing of in-vitro diagnostic solutions. Its product line encompasses reagents for autoimmune conditions, IMMUNO-TROL — a comprehensive quality control tool with multiple parameters — and various instruments for testing both autoimmune disorders and infectious diseases. Among its unique offerings are the SQA-V system, engineered for semen analysis, and V-Sperm, a specialized application for digitally uploading and viewing sample results, including pictures and video recordings. The company's advanced instrumentation includes Theralis, which integrates multiplex FIDIS immunofluorescence with ELISA capabilities; Theralis µ, designed as a suitable solution for mid-sized laboratories; and the FIDIS platform, utilized for diverse laboratory analyses. Furthermore, Theradiag provides therapeutic drug monitoring services aimed at managing chronic inflammatory conditions. It also offers LISA tracker, an essential device for overseeing biotherapies, alongside both ELISA and rapid serological tests for SARS-CoV-2. Founded in 1986, Theradiag S.A. is based in Marne La Vallee, France.

Έτος	Κέρδη	Αλλαγή
Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Έτος

Κέρδη

Αλλαγή

Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Εταιρεία	Κέρδη	Διαφορά Κερδών	Χώρα
Abbott Laboratories ABT.US	$7.51B	-	US
Stryker Corporation SYK.US	$5.15B	-	US
Medtronic plc MDT.US	$5.56B	-	IE
Boston Scientific Corporation BSX.US	$3.86B	-	US
Edwards Lifesciences Corporation EW.US	$1.42B	-	US

Εταιρεία

Κέρδη

Διαφορά Κερδών

Χώρα